Impact of introduction of the 9-valent human papillomavirus vaccine on vaccination coverage of youth in North Carolina

被引:2
|
作者
Trogdon, Justin G. [1 ]
Shafer, Paul [1 ]
Lindsay, Brianna [2 ]
Coyne-Beasley, Tamera [3 ]
机构
[1] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, 1101 McGavran Greenberg Hall,Campus Box 7411, Chapel Hill, NC 27599 USA
[2] Univ Penn, Sch Arts & Sci, Philadelphia, PA 19104 USA
[3] Univ N Carolina, Dept Pediat, 260 MacNider Bldg,Campus Box 7220, Chapel Hill, NC 27599 USA
关键词
Human papillomavirus; Vaccination; Interrupted time series; AGED; 13-17; YEARS; COST-EFFECTIVENESS; UNITED-STATES; ADVISORY-COMMITTEE; HPV VACCINATION; CERVICAL-CANCER; POLIO ENDGAME; RECOMMENDATIONS; HEALTH;
D O I
10.1016/j.vaccine.2018.01.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: The objective of this study was to evaluate the impact of introduction of 9vHPV vaccine on HPV vaccination uptake (doses per capita) and initiation (>= 1 doses), completion (>= 3 doses) and compliance (>= 3 doses within 12 months) by adolescents. Methods: We used a retrospective cohort analysis using North Carolina Immunization Registry (NCIR) data from January 2008 through October 2016. The sample included Vaccines for Children eligible adolescents aged 9 to 17 years in 2016, for whom the NCIR contains complete vaccination history. We applied an interrupted time series design to measure associations between ZIP Code Tabulation Area (ZCTA)-level HPV vaccination outcomes over time with the introduction of 9vHPV in North Carolina (NC) in July 2015. Results: Each outcome displayed a linear upward trend over time with large seasonal spikes near August of each year, corresponding to the time when adolescents often receive other vaccines required for school entry. After accounting for these underlying trends, introduction of 9vHPV was not associated with a change in publicly funded HPV vaccination rates in NC. Conclusions: Our results indicate that 9vHPV substituted for 4vHPV in the first year after release in NC, but the release of 9vHPV was not associated with an overall change in HPV vaccination. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1304 / 1309
页数:6
相关论文
共 50 条
  • [1] Determinants of the receipt of the 9-valent human papillomavirus vaccine in the first year after introduction in North Carolina
    Trogdon, Justin G.
    Shafer, Paul
    Lindsay, Brianna
    Coyne-Beasley, Tamera
    VACCINE, 2018, 36 (10) : 1310 - 1315
  • [2] Safety of the 9-Valent Human Papillomavirus Vaccine
    Shimabukuro, Tom T.
    Su, John R.
    Marquez, Paige L.
    Mba-Jonas, Adamma
    Arana, Jorge E.
    Cano, Maria, V
    PEDIATRICS, 2019, 144 (06)
  • [3] The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
    Cheung, Tak Hong
    Cheng, Sally Shuk Yee
    Hsu, Danny C.
    Wong, Queenie Wing-Lei
    Pavelyev, Andrew
    Walia, Anuj
    Saxena, Kunal
    Prabhu, Vimalanand S.
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [4] Extended surveillance to assess safety of 9-valent human papillomavirus vaccine
    Sundaram, Maria E.
    Kieke, Burney A.
    Hanson, Kayla E.
    Belongia, Edward A.
    Weintraub, Eric S.
    Daley, Matthew F.
    Hechter, Rulin C.
    Klein, Nicola. P.
    Lewis, Edwin. M.
    Naleway, Allison L.
    Nelson, Jennifer C.
    Donahue, James G.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 18 (07)
  • [5] Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium
    Simoens, Steven
    Bento-Abreu, Andre
    Merckx, Barbara
    Joubert, Sophie
    Vermeersch, Steve
    Pavelyev, Andrew
    Varga, Stefan
    Morais, Edith
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [6] A Broad Safety Assessment of the 9-Valent Human Papillomavirus Vaccine
    Yih, W. Katherine
    Kulldorff, Martin
    Dashevsky, Inna
    Maro, Judith C.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2021, 190 (07) : 1253 - 1259
  • [7] Update on the new 9-valent vaccine for human papillomavirus prevention
    Yang, David Yi
    Bracken, Keyna
    CANADIAN FAMILY PHYSICIAN, 2016, 62 (05) : E236 - E240
  • [8] Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination
    Siok Shen Ng
    Hutubessy, Raymond
    Chaiyakunapruk, Nathorn
    VACCINE, 2018, 36 (19) : 2529 - 2544
  • [9] Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine
    Zhang, Zhigang
    Zhang, Jun
    Xia, Ningshao
    Zhao, Qinjian
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (10) : 2280 - 2291
  • [10] The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
    Tak Hong Cheung
    Sally Shuk Yee Cheng
    Danny C. Hsu
    Queenie Wing-Lei Wong
    Andrew Pavelyev
    Anuj Walia
    Kunal Saxena
    Vimalanand S. Prabhu
    Cost Effectiveness and Resource Allocation, 19